MiMedx Group, Inc $MDXG is Meros Investment Management LP's 8th Largest Position

Key Points

• Meros Investment Management LP increased its stake in MiMedx Group, acquiring an additional 425,531 shares, which boosted its ownership by 107.7% during the first quarter.
• MiMedx Group recently reported $0.10 earnings per share (EPS), surpassing analysts' expectations of $0.06, with revenue of $98.61 million for the quarter.
• Analysts have raised their price targets for MiMedx Group, with Cantor Fitzgerald increasing its target from $11.00 to $12.00 and Wall Street Zen upgrading the stock to a "strong-buy" rating.

Meros Investment Management LP increased its position in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 107.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 820,605 shares of the company's stock after acquiring an additional 425,531 shares during the period. MiMedx Group makes up about 3.7% of Meros Investment Management LP's investment portfolio, making the stock its 8th biggest position. Meros Investment Management LP owned approximately 0.56% of MiMedx Group worth $6,237,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtus Fund Advisers LLC acquired a new stake in MiMedx Group in the 4th quarter valued at $35,000. Tower Research Capital LLC TRC grew its holdings in shares of MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. Ameriprise Financial Inc. bought a new position in shares of MiMedx Group during the fourth quarter valued at approximately $115,000. Legato Capital Management LLC bought a new position in shares of MiMedx Group during the first quarter valued at approximately $101,000. Finally, Sowell Financial Services LLC acquired a new position in shares of MiMedx Group during the first quarter worth approximately $115,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on MDXG shares. Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Cantor Fitzgerald boosted their target price on MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $12.00.

MiMedx Group Trading Down 1.5%

MiMedx Group stock traded down $0.1110 during trading hours on Thursday, hitting $7.0590. The company had a trading volume of 63,403 shares, compared to its average volume of 686,591. The firm has a market cap of $1.04 billion, a P/E ratio of 33.62 and a beta of 1.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.90 and a current ratio of 4.39. MiMedx Group, Inc has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a 50-day moving average price of $6.61 and a two-hundred day moving average price of $7.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.04. The company had revenue of $98.61 million during the quarter, compared to analysts' expectations of $90.79 million. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. On average, sell-side analysts anticipate that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.